血清 FBLN1 和 STK31 作为结直肠癌的生物标志物及其用于非侵入性区分结直肠癌与良性息肉的能力。

Serum FBLN1 and STK31 as biomarkers of colorectal cancer and their ability to noninvasively differentiate colorectal cancer from benign polyps.

机构信息

Clinical Pathology Department, Faculty of Medicine, Tanta University Hospital, El-Geesh St., Tanta, Egypt.

Tanta University Hospital, Clinical Oncology Department, Faculty of Medicine, El-Geesh St., Tanta, Egypt.

出版信息

Clin Chim Acta. 2018 Aug;483:151-155. doi: 10.1016/j.cca.2018.04.038. Epub 2018 Apr 30.

DOI:10.1016/j.cca.2018.04.038

PMID:29715435

Abstract

PURPOSE

The aim of this work is to evaluate Fibulin-1 (FBLN1) and serine threonine kinase-31 (STK31) as colorectal cancer (CRC) tumour markers and their ability to differentiate it from colorectal benign lesions.

MATERIAL AND METHODS

In this case-control study, FBLN1 and STK31 serum levels were measured in 120 participants; 49 CRC patients (group I), 26 patients with benign colorectal polyps (group II) and 45 healthy controls (group III).

RESULTS

The means of serum FBLN1 were 1.02 ± 0.95, 6.36 ± 2.55 and 6.26 ± 2.76 in group I, II and III respectively. Significant lower levels were found in group I compared to group II and III (both p < 0.001) with no significant difference between group II and III (p = .983). The means of serum STK31 were 13.51 ± 7.67, 5.98 ± 3.3 and 1.37 ± 1.22 in group I, II and III respectively with significant differences in-between the 3 groups (p < 0.001). Both FBLN1 and STK31 were superior to CEA as CRC screening biomarkers; with sensitivity 90.1% and 93% respectively and specificity 93.9% and 95.9% respectively. FBLN1 differentiated CRC from benign polyps with 91.8% sensitivity and 100% specificity. STK31 differentiated CRC from benign polyps with 93.9% sensitivity and 84.6% specificity.

CONCLUSION

FBLN1 and STK31 can be possible screening and differentiating biomarkers of CRC.

摘要

目的

本研究旨在评估纤维结合素 1（FBLN1）和丝氨酸苏氨酸激酶 31（STK31）作为结直肠癌（CRC）肿瘤标志物的能力，并评估其区分CRC 与结直肠良性病变的能力。

材料与方法

在这项病例对照研究中，检测了 120 名参与者的血清 FBLN1 和 STK31 水平；其中 49 例 CRC 患者（I 组）、26 例结直肠良性息肉患者（II 组）和 45 名健康对照者（III 组）。

结果

I、II 和 III 组的血清 FBLN1 均值分别为 1.02±0.95、6.36±2.55 和 6.26±2.76。与 II 组和 III 组相比，I 组的 FBLN1 水平显著降低（均 p<0.001），而 II 组和 III 组之间无显著差异（p=0.983）。I、II 和 III 组的血清 STK31 均值分别为 13.51±7.67、5.98±3.3 和 1.37±1.22，三组之间差异有统计学意义（p<0.001）。FBLN1 和 STK31 作为 CRC 筛查生物标志物均优于 CEA，其敏感性分别为 90.1%和 93%，特异性分别为 93.9%和 95.9%。FBLN1 对 CRC 与良性息肉的鉴别诊断具有 91.8%的敏感性和 100%的特异性。STK31 对 CRC 与良性息肉的鉴别诊断具有 93.9%的敏感性和 84.6%的特异性。